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Abstract
Background: Toll-like-receptor 4 (TLR) is discussed to provide a molecular link between obesity, inflammation and insulin
resistance. Genetic studies with replications in non-diabetic individuals in regard to their fat distribution or insulin
resistance according to their carrier status of a common toll-like receptor 4 (TLR4) variant (TLR4
D299G/T399I) are still
lacking.
Methodology/Principal Findings: We performed a cross-sectional analysis in individuals phenotyped for prediabetic
traits as body fat composition (including magnetic resonance imaging), blood glucose levels and insulin resistance (oral
glucose tolerance testing, euglycemic hyperinsulinemic clamp), according to TLR4 genotype determined by candidate
SNP analyses (rs4986790). We analyzed N=1482 non-diabetic individuals from the TU ¨F/TULIP cohort (South Germany,
aged 39613 y, BMI 28.567.9, mean6SD) and N=5327 non-diabetic participants of the METSIM study (Finland, males
aged 5866 y, BMI 26.863.8) for replication purposes. German TLR4
D299G/T399I carriers had a significantly increased body
fat (XG in rs4986790: +6.98%, p=0.03, dominant model, adjusted for age, gender) and decreased insulin sensitivity (XG:
215.3%, Matsuda model, p=0.04; XG: 220.6%, p=0.016, clamp; both dominant models adjusted for age, gender, body
fat). In addition, both liver fat (AG: +49.7%; p=0.002) and visceral adipose tissue (AG: +8.2%; p=0.047, both adjusted for
age, gender, body fat) were significantly increased in rs4986790 minor allele carriers, and the effect on liver fat
remained significant also after additional adjustment for visceral fat (p=0.014). The analysis in METSIM confirmed
increased body fat content in association with the rare G allele in rs4986790 (AG: +1.26%, GG: +11.0%; p=0.010, additive
model, adjusted for age) and showed a non-significant trend towards decreased insulin sensitivity (AG: 20.99%,
GG: 210.62%).
Conclusions/Significance: TLR4
D299G/T399I associates with increased total body fat, visceral fat, liver fat and decreased insulin
sensitivity in non-diabetic Caucasians and may contribute to diabetes risk. This finding supports the role of TLR4 as a
molecular link between obesity and insulin resistance.
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Introduction
Obesity and excess of saturated free fatty acids (SFFAs) cause
low-grade inflammatory processes with subsequent development of
insulin resistance, which is a major risk factor for later onset of
type 2 diabetes mellitus [1]. As the prevalence of obesity and type
2 diabetes mellitus (T2DM) increases throughout the world with
remarkable socio-economic impact [2], it is important to
understand the molecular mechanisms that link dietary SFFA
intake and endogenous SFFAs derived from adipose tissue
lipolysis, respectively, to inflammation.
In this context, toll-like receptor (TLR) signaling moved into the
center of current scientific debate [3]. TLRs are transmembrane
receptors which play a crucial role in the innate, non-adaptive
immune system. The human TLR family comprises at least 13
distinctive proteins (TLR1 – TLR13) that are able to recognize
typical microbial agents and subsequently facilitate an early
immune response via downstream signaling to different signaling
pathways (see [4,5,6] for review). The human TLR member
characterized best to date is toll-like receptor 4 (TLR4;
NM_138554; OMIM 603030), as this signaling molecule is
essential for the recognition of bacterial lipopolysaccharides
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13980(LPS) beyond other microbial agents [7]. LPS represent a key
element of gram-negative bacteria and contain fatty acids in their
lipid-A domain anchoring LPS into the bacterial cell wall [8]. First
evidence that TLR4 not only acts for LPS as a signaling receptor
but also for other lipids as e.g. SFFAs came up from studies in
macrophages expressing TLR4 mutants [9]. Subsequent studies
revealed that TLR4 signaling actually is essential for the
development of SFFA-induced insulin resistant states in different
cellular models, as e.g. in 3T3L1-adipocytes [10,11] and L6
myotubes [12]. It was also shown that TLR4 mediates the
crosstalk between macrophage-induced adipose tissue lipolysis and
increased inflammatory activity in both adipocytes and macro-
phages [13]. In addition, TLR4
2/2 mice are protected against
down-regulation of insulin signaling in skeletal muscle upon
systemic lipid infusion [11,12], and C3H/HeJ mice bearing a loss-
of-function mutation in TLR4 do not develop diet-induced obesity
or insulin-resistance in skeletal muscle [14], nor do they develop
dietary hepatic steatosis [15]. A very recent molecular study
provides further insights into the molecular events occurring after
SFFA-induced TLR4 receptor stimulation, as both TLR4
dimerization and its recruitment to lipid-rafts seem to be
influenced by SFFAs [16]. In humans, obese and type 2 diabetic
subjects show both an increased TLR4 gene expression and TLR4-
dependent activation of the inflammatory signaling molecules
IkB/NFkB [17], and dietary restriction results in down-regulation
of TLR4 expression [18].
In summary, there is evidence that TLR4 may provide the
molecular mechanism that links increased SFFAs in obese subjects
to the observed chronic low-grade inflammatory state and
subsequent manifestation of insulin resistance. Further evidence
for the potential in-vivo relevance of this mechanism would result
from genetic studies in populations with common TLR4 mutants.
In this regard, two SNPs (rs4986790, rs4986791) in exon 3 of the
TLR4 gene (TLR4) causing single amino acid replacements
(rs4986790: D299G; rs4986791: T399I) in the extracellular
TLR4 domain were shown to be present at allele frequencies
between 0.03 and 0.05 in different Caucasian populations [19]. In
Europeans, co-segregation (D’=1.0, r
2=1.0) of both SNPs occurs
[20], probably owing to genetic drift after selection of the
TLR4
D299G mutant in Africa which confers resistance to malaria
[21]. As the two non-synonymous SNPs rs4986790/91 in the
extracellular domain of TLR4 may bear functional consequences
on ligand-binding, many studies focused on the relevance of
rs4986790/91 on both the cellular level and in genetic association
studies, revealing conflicting results [22].
Most geneticists focused on immunologic and inflammatory
phenotypes associating with the TLR4
D299G/T399I variant
[23,24,25,26,27,28], and only a limited number of studies
addressing the role of TLR4
D299G/T399I for diabetic traits are
available. While an early study was not able to verify the
association of TLR4
D299G/T399I with changes in diabetes preva-
lence [29], a recent work supports that male Caucasian
TLR4
D299G/T399I individuals are at higher T2DM risk, dependent
on the ratio between (total):(high-density-lipoprotein) cholesterol
levels [30]. In addition, increased risk of early onset of diabetic
retinopathy was reported for TLR4
D299G/T399I carriers in Brasil
[31]. On the other hand, the prevalence of diabetic neuropathy
seemed to be lower in TLR4
D299G/T399I Caucasian individuals
[32], and protection from both T2DM [33] and the metabolic
syndrome [34] by TLR4
D299G/T399I also has been described.
To our knowledge, there are no investigations that have
addressed potential prediabetic phenotypes in carriers of the
TLR4
D299G/T399I variant. We, therefore, conducted this genetic
association study on TLR4
D299G/T399I in non-diabetic subgroups
of two independent Caucasian populations, namely the TU ¨F/
TULIP cohort (South Germany) and the METSIM cohort
(Finland). We focused on both body composition parameters as
well as insulin resistance in light of above listed TLR4 signaling
functions.
Materials and Methods
Study Participants
TU ¨F/TULIP cohort – 1635 participants of the Tu ¨bingen
Family Study (TU ¨F) and the Tu ¨bingen Lifestyle Intervention
Program (TULIP) in South West Germany were analyzed for this
study. All volunteers signed informed written consent to the study
protocol which was approved by the local medical ethics
committee. 153 subjects had to be excluded owing to manifest
diabetes or missing data resulting in a total cohort of n=1482
non-diabetic individuals. The participants (see Table 1 for
additional characteristics) did not take any medication known to
affect glucose tolerance, and strict abstention from smoking was
demanded 24 h before and during the test period including an oral
glucose tolerance test (OGTT; all participants, see below) and a
hyperinsulinaemic-euglycaemic clamp (N=502 participants). As
described elsewhere [35], the aim of the TULIP study is to provide
a broad range of metabolic data of non-diabetic individuals with
increased diabetes risk, as e.g. a positive family history of diabetes,
a BMI of .27 kg/m
2, the presence of impaired fasting glucose
(IFG) or former gestational diabetes.
METSIM cohort – The METabolic Syndrome In Men
(METSIM) Study is a population-based random sample of 6229
Finnish men aged from 45 to 73 years in Eastern Finland (Kuopio,
see Table 1) who were phenotyped during a one-day visit to the
Clinical Research Unit of the University of Kuopio for diabetes
risk and cardiovascular disease variables. All study participants
underwent an OGTT, and the study protocol was approved by the
local ethics committee. For this study, only non-diabetic METSIM
participants were analyzed (N=5327). However, additional
inclusion of METSIM participants with diagnosed diabetes
(N=898) according to the WHO criteria [36] allowed estimation
for diabetes risk using logistic regression analysis in a separate
analysis.
Table 1. Clinical characteristics of the TU ¨F-TULIP and METSIM
study population.
TU ¨ F-TULIP METSIM
Gender (female/male) 978/504 0/5327
IFG/IGT/(IFG+IGT) 48/193/59 884/503/346
Age (y) 39613 5866
BMI (kg/m
2)2 8 . 5 67.9 26.863.8
Body Fat (%) 30.4610.4 23.966.5
Fasting glucose (mmol/l) 5.1160.57 5.6860.50
Glucose, 120 min OGTT (mmol/l) 6.2661.67 6.0961.69
Fasting insulin (pmol/l) 62.2651.1 48.6633.7
Insulin, 30 min OGTT (pmol/l) 4246443 3916284
Data are given as means 6SD. BMI – body mass index; IFG – impaired fasting
glucose (defined as 100–126 mg/dl according to AHA guidelines); IGT –
impaired glucose tolerance; OGTT – oral glucose tolerance test.
doi:10.1371/journal.pone.0013980.t001
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A bedside glucose analyzer (Yellow Springs Instruments, Yellow
Springs, OH, USA) was used to measure blood glucose. Plasma
insulin was determined by commercial chemiluminescence assays
from ADVIA Centaur (Siemens Medical Solutions, Fernwald,
Germany; unit: pmol/l). In the METSIM Study, plasma glucose
was measured by enzymatic hexokinase photometric assay
(Konelab Systems Reagents, Thermo Fischer Scientific, Vantaa,
Finland), and insulin was determined by immunoassay (ADVIA
Centaur Insulin IRI, no 02230141, Siemens Medical Solutions
Diagnostics, Tarrytown, NY; unit: mU/l) according to the
manufacturer’s instructions.
Oral glucose tolerance test (OGTT)
TU ¨F/TULIP and METSIM participants were investigated in
the fasting state at baseline. Subsequently, all participants
underwent an OGTT performed according to the WHO
recommendations [37]. Blood glucose and plasma insulin were
determined at 0, 30, 60, 90 and 120 min in the TU ¨F/TULIP
Study and at 0, 30, and 120 min in the METSIM Study.
Determination of body and liver fat
The body mass index (BMI) was calculated as weight divided by
the square of height (kg/m
2). Body fat was determined by
bioelectrical impedance (RJL; Detroit, MI, USA). In the TULIP
cohort, liver fat was determined by magnetic resonance spectros-
copy (1.5 T Magnetom Sonata; Siemens, Erlangen, Germany) in
the posterior 7
th segment of the liver. A single-voxel stimulated
echo acquisition mode technique was used (repetition time=4 s,
echo time=10 msec, 32 acquisitions) for a voxel of 36362c m
3,
and liver fat content was calculated by the signal integral
(methylene/methyl signals between 0.7–1.5 ppm) in reference to
the sum of water and lipid signal integrals [38,39].
Insulin sensitivity
Insulin sensitivity was estimated using the Matsuda model [40]
in both study cohorts, based on plasma glucose and plasma insulin
levels obtained at 0, 30, 60, 90 and 120 min in TU ¨F/TULIP and
0, 30, 120 min in METSIM, respectively. In the METSIM cohort,
we additionally used the Homeostasis Model Assessment of Insulin
Resistance (HOMA-IR) for estimation of insulin resistance [41]. In
N=502 TU ¨F/TULIP participants, an additional hyperinsulinae-
mic euglycaemic clamp was undertaken during a second visit.
Further details on the clamping technique are described elsewhere
[42].
Genotyping
The SNP rs4986790 (exon 3) encoding the D299G mutation in
the extracellular domain of TLR4 was genotyped by use of the
TaqMan assay (Eurogentec; Liege, Belgium) and the fluorescence
detecting ABI Prism 7500 (Applied Biosystems; Foster City, CA,
USA). To verify the reported co-segregation of rs4986790 (exon 3,
D299G) with rs4986791 (exon3, T399I; D’=1.0, r
2=1.0 in the
CEU population, HapMap Rel #24 PhaseII Nov08 [20]) and
TaqMan validity in our cohort, we sequenced for both SNPs in
N=388 German participants, verifying the reported linkage
disequilibrium (D’=1.0, r
2=1.0). Genotyping quality was ensured
by including three sequenced controls of each rs4986790 genotype
in the TaqMan assay plates.
Statistics
The JMP 4.0.4 software (SAS Institute; Cary, NC, USA) and
SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA) were used
for statistical analysis. Data are presented as means 6 SD if not
otherwise stated. The x
2-test was used for testing Hardy-
Weinberg-Equilibrium. All non-normally distributed parameters
were logarithmically transformed before analysis by ANOVA or t-
tests without adjustment or with adjustment to relevant covariates
in linear regression models. A p value#0.05 was considered
statistically significant.
Results
Distribution of D299I-TLR4 genotypes
The genotype call rate for rs4986790 was 98.2/100% in the
TU ¨F/TULIP and the METSIM Study, respectively. The minor
allele frequency of rs4986790 was 0.052 in TU ¨F/TULIP and
0.094 in METSIM, and both genotype distributions were in
Hardy-Weinberg-Equilibrium (TU ¨F/TULIP: p=0.86; METSIM:
p=0.64).
D299G-TLR4 association analyses in TU ¨F/TULIP
Associations in this population were only calculated based on a
dominant model owing to the low minor allele frequency of
rs4986790 in TU ¨F/TULIP, resulting in 3 homozygote minor
allele carriers. The minor allele carriers of rs4986790 had a
significantly increased body fat (e.g. XG: +6.98%, p=0.03 in the
dominant model adjusted for age and gender, see Table 2), and an
allele-dose effect on body fat could be assumed (AG: +6.9%, GG:
+9.2%; see also results of METSIM below). There was no
significant association between rs4986790 genotype and BMI or
blood glucose (both 0 and 120 min OGTT) levels (p.0.06; all). In
contrast, insulin sensitivity was significantly decreased in
rs4986790 minor allele carriers, independently of whether the
Matsuda estimation model (XG: 215.3%) or insulin sensitivity
data measured by clamp (XG: 220.6%) were used for analysis.
This association remained significant after adjustment for age,
gender and BMI (see Table 2) or body fat (Matsuda: p=0.04;
clamp: p=0.016; dominant model). We additionally stratified the
TU ¨F/TULIP cohort for gender, as the METSIM cohort only
includes male participants. While the association with body fat
(p=0.04, adjusted for age; dominant model) and insulin sensitivity
(Matsuda: p=0.002; clamp: p=0.013, both adjusted for age,
gender and BMI; dominant model) was more significant in males,
both association analyses turned out to be non-significant in
women (body fat: p=0.24, Matsuda/clamp: p.0.53).
As liver fat is an important determinant for insulin resistance
[43], we subsequently analyzed whether the rs4986790 genotype
also associates with liver fat measured by magnetic resonance
imaging (MRI). Indeed, liver fat was significantly increased in
heterozygous rs4986790 minor allele carriers (AG: +49.7%;
N=297, no liver fat data from homozygous carriers available;
see Figure 1). In addition, visceral adipose tissue (VAT) content in
rs4986790 SNP carriers was significantly higher (AG: +8.2%;
p=0.047, adjusted for age, gender and body fat) in the subgroup
where VAT was determined by MRI (N=315, no homozygous
genotypes available, data not shown). The liver fat analysis
remained significant after adjustment for VAT (p=0.014, adjusted
for age, gender, body fat and VAT).
D299I-TLR4 association analyses in METSIM
The association of rs4986790 genotype with body fat was
reproducible in METSIM (AG: +1.26%, GG: +11.0%; p=0.010,
additive model, see Table 3). Similarly as in TU ¨F/TULIP, BMI
and blood glucose levels were not associated with the rs4986790
genotype (p.0.10; all). Insulin sensitivity (Matsuda model) also
decreased in rs4986790 G allele carriers (AG: 20.99%, GG:
TLR4 and Body Fat Composition
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accordingly increased (AG: +0.96%, GG: +2.07%, see Table 3).
However, this effect remained non-significant, independent of the
used genetic calculation model or adjustment to BMI (or body fat)
and age (p.0.21, all). Logistic regression analysis comparing
diabetic with non-diabetic METSIM study participants did not
reveal a significantly altered diabetes prevalence in rs4986790
minor allele (p.0.264, additive and dominant model). In contrast
to the findings of Kolz et al. [30], interaction analysis of TLR4
rs4986790 genotype by the ratio of total-cholesterol:HDL-
cholesterol (TC/HDL-C) was not significant (p=0.28; dominant
model). Stratification of the METSIM cohort for TC/HDL-C
was, therefore, not admissible.
Discussion
This is the first study to have investigated the role of the
TLR4
D299G/T399I double mutant for body fat composition and
insulin resistance in non-diabetic populations at increased diabetes
risk. Our finding is a consistent association of the minor allele of
the selected tagging SNP rs4986790 with increased body fat in
both the TU ¨F/TULIP and the METSIM study cohort. The effect
on body fat was remarkable in both populations, especially in
homozygous minor allele rs4986790 carriers (+9.2% and +11.0%,
respectively). In the German cohort, there were also significant
associations of the minor G allele in rs4986790 with increased
insulin resistance, increased liver fat and increased visceral fat in
adjusted linear models. In METSIM, there was only a non-
significant trend to reduced insulin sensitivity. We assume that this
finding may be a consequence of the different structure of both
study populations. In METSIM, participants were selected
randomly from the population of Kuopio and are older by an
average of 20 years, while TU ¨F/TULIP comprises mainly non-
diabetic individuals at a younger age, selected based on the
assumption of an increased diabetes risk.
The link between the innate immune system and obesity comes
from common features of both macrophages and adipocytes. Both
cell types secrete various pro-inflammatory chemokines and
cytokines and intensely interact yet due to their close physical
location in adipose tissue [44,45], and both adipocytes and
macrophages express TLR4 on their plasma membrane [4,10].
TLR4 expression in visceral adipose tissue (VAT) of obese subjects
exceeds that of the subcutaneous fat compartment, in contrast to
lean individuals, where TLR4 is expressed more in subcutaneous
fat compared to VAT [46]. A recent study also showed that TLR4
expression is increased on VAT-derived macrophages from both
obese and diabetic individuals, and that both adipocyte size and
systemic CRP levels are increased according to macrophage
infiltration and TLR4 expression [47]. Taken together, these data
yet support our finding that a TLR4 variant impacts on body fat
composition and insulin resistance.
Above mentioned studies let assume that the TLR4
D299G/T399I
double mutant confers an intrinsic activation to TLR4, at least in
adipose tissue and liver fat. However, functional assays with
TLR4
D299G/T399I revealed inconclusive results. While some
authors reported hypo-responsiveness of this TLR4 mutant to
stimuli like e.g. LPS [25], other groups could not verify any
Table 2. Associations of TLR4 SNP rs4986790 (D299G) with anthropometric and metabolic data in the TU ¨F-TULIP cohort (N=1482).
SNP rs4986790 dominant model
Genotype AA AG GG p1 p2
N 1330 149 3
Age (y) 39613 39613 2963 0.86 0.96
BMI (kg/m
2) 28.467.8 29.568.6 29.9610.2 0.11 0.13
Body Fat (%) 30.2610.4 32.3610.7 33.0618.0 0.02 0.03
Fasting glucose (mM) 5.1160.57 5.1760.58 4.8460.15 0.25 0.42
Glucose, 120 min OGTT (mM) 6.2361.67 6.4861.59 7.3061.92 0.06 0.09
Insulin sensitivity (Matsuda), OGTT (AU) 16.8611.0 14.2669.0 11.3366.1 0.004 0.03
Insulin sensitivity, clamp (U)* 0.08760.056 0.06960.046 0.06960.069 0.026 0.04
Data are given as means 6SD. p1 – non-adjusted model; p2 – adjusted model with log-transformed data; age was adjusted for gender; BMI and body fat were adjusted
for gender and age; glucose levels as well as insulin sensitivity (Matsuda estimation model, clamp) were adjusted for gender, age, and BMI; BMI – body mass index; OGTT
– oral glucose tolerance test; SNP – single nucleotide polymorphism.
*N=502.
doi:10.1371/journal.pone.0013980.t002
Figure 1. Liver fat according to D299G-TLR4 (rs4986790)
genotype. Liver fat was determined by magnetic resonance imaging
in the German cohort in 297 participants. Indicated p-values refer to the
non-adjusted/adjusted model, with adjustments for age, gender and
BMI (alternative adjustment for body fat did not alter significance). Data
are presented as mean +SEM.
doi:10.1371/journal.pone.0013980.g001
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D299G/T399I
to wildtype TLR4 [27]. Therefore, future studies should address
adipocyte TLR4 signaling in adipose tissue samples derived from
TLR4
D299G/T399I carriers to finally address this issue.
One could speculate that differences in serum free fatty acid
(FFA) levels may have contributed to the reported phenotype with
higher body fat content. However, serum FFA levels did not differ
in TU ¨F/TULIP according to TLR4 genotype, and systemic
cytokines (TNFa, IL6) as a possible readout of inflammatory
activity were also not altered significantly (data not shown). As the
effect on liver fat was independent of the increased VAT content
in German TLR4
D299G/T399I carriers, we assume that the
observed increase in ectopic hepatic fat may be a consequence
from altered direct crosstalk between hepatic macrophages and
adipocytes, and not an epiphenomen caused by potential VAT
mediator release. It is well known that liver fat generally associates
with insulin resistance [48,49], but we also have learned that this
association is subject to remarkably high variability [43]. Taking
into account that the increase in liver fat in TLR4
D299G/T399I
carriers comes along with decreased insulin sensitivity in TU ¨F/
TULIP, one may speculate whether TLR4 may represent a
candidate for the mediation of metabolically unfavorable effects of
liver fat.
The limitation of our study is that Bonferroni’s correction for 3
independent endpoints (body fat, plasma glucose, insulin sensitiv-
ity, expected a-level: 0.017) would render the reported finding for
body fat composition nominal. In addition, the increase in body fat
in non-diabetic individuals was not reflected by a significant
increase in diabetes prevalence in the METSIM study.
In summary, we conclude that the TLR4
D299G/T399I double
mutant is associated with increased body fat and insulin resistance.
Due to its low allele frequency throughout different populations
[21], TLR4
D299G/T399I cannot be seen as a strong obesity or
diabetes risk gene, but may contribute to factors that are well
known to entail a relevant predisposition to later onset of type 2
diabetes mellitus.
Acknowledgments
We gratefully acknowledge the technical assistance of Melanie Weisser,
Alke Guirguis, Roman Werner and Anna Bury. The authors would also
like to thank all participants for their cooperation.
Author Contributions
Conceived and designed the experiments: PW NS ML AF HUH.
Performed the experiments: FM JM SAS. Analyzed the data: PW HS
AS JK AF. Contributed reagents/materials/analysis tools: FM JM FS ML
HUH. Wrote the paper: PW. Revised/edited the manuscript: HS AS FS
NS JK ML SAS AF HUH. Contributed to discussion: HS AS FM JM FS
NS JK ML SAS AF HUH.
References
1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, et al. (2006) Recent
advances in the relationship between obesity, inflammation, and insulin
resistance. Eur Cytokine Netw 17: 4–12.
2. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the
diabetes epidemic. Nature 414: 782–787.
3. Fessler MB, Rudel LL, Brown JM (2009) Toll-like receptor signaling links
dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol.
4. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol
1: 135–145.
5. Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their
ligands. Annu Rev Biochem 76: 141–165.
6. O’Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10
years of progress. Immunol Rev 226: 10–18.
7. Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S (2007) Toll-like receptor
signal transduction. Exp Mol Med 39: 421–438.
8. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev
Biochem 71: 635–700.
9. Lee JY, Sohn KH, Rhee SH, Hwang D (2001) Saturated fatty acids, but not
unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated
through Toll-like receptor 4. J Biol Chem 276: 16683–16689.
10. Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of Toll-like receptor 4 is
associated with insulin resistance in adipocytes. Biochem Biophys Res Commun
346: 739–745.
11. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links
innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:
3015–3025.
12. Radin MS, Sinha S, Bhatt BA, Dedousis N, O’Doherty RM (2008) Inhibition or
deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial
protection against lipid-induced insulin resistance in rodent skeletal muscle.
Diabetologia 51: 336–346.
13. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, et al. (2007)
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-
induced inflammatory changes in the interaction between adipocytes and
macrophages. Arterioscler Thromb Vasc Biol 27: 84–91.
14. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM,
et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-
induced obesity and insulin resistance. Diabetes 56: 1986–1998.
15. Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, et al. (2007) C3H/HeJ
mice carrying a toll-like receptor 4 mutation are protected against the
development of insulin resistance in white adipose tissue in response to a high-
fat diet. Diabetologia 50: 1267–1276.
Table 3. Associations of TLR4 SNP rs4986790 (D299G) with anthropometric and metabolic data in the METSIM cohort (N=5327).
SNP rs4986790 additive dominant
Genotype AA AG GG p1 p2 p1 p2
N 4375 902 50
Age (y) 58665 9 675 9 67 0.57 - 0.29 -
BMI (kg/m
2)2 6 . 9 63.8 26.763.8 27.863.7 0.10 0.10 0.58 0.59
Body Fat (%) 23.966.4 24.266.6 26.566.7 0.015 0.010 0.10 0.19
Fasting glucose (mM) 5.6860.50 5.6960.49 5.7160.53 0.77 0.67 0.48 0.41
Glucose, 120 min OGTT (mM) 6.0861.68 6.1361.74 6.3361.65 0.43 0.61 0.39 0.38
Insulin sensitivity (Matsuda), OGTT (AU) 7.0564.19 6.9764.14 6.3163.27 0.61 0.36 0.46 0.21
Insulin resistance index (HOMA-IR), OGTT (AU) 2.07861.509 2.08061.535 2.12161.335 0.83 0.52 0.76 0.38
Data are given as means 6SD. p values were calculating using log-transformed variables. p1 – non-adjusted model; p2 – adjusted model as follows: BMI and body fat
were adjusted for age; glucose levels as well as insulin sensitivity (Matsuda estimation model; Homeostasis Model Assessment of Insulin Resistance: HOMA-IR) were
adjusted for age and BMI; BMI – body mass index; OGTT – oral glucose tolerance test; SNP – single nucleotide polymorphism.
doi:10.1371/journal.pone.0013980.t003
TLR4 and Body Fat Composition
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e1398016. Wong SW, Kwon MJ, Choi AM, Kim HP, Nakahira K, et al. (2009) Fatty acids
modulate toll-like receptor 4 activation through regulation of receptor
dimerization and recruitment into lipid rafts in a ros-dependent manner. J Biol
Chem.
17. Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, et al. (2008) Elevated
toll-like receptor 4 expression and signaling in muscle from insulin-resistant
subjects. Diabetes 57: 2595–2602.
18. de Mello VD, Kolehmainen M, Pulkkinen L, Schwab U, Mager U, et al. (2008)
Downregulation of genes involved in NFkappaB activation in peripheral blood
mononuclear cells after weight loss is associated with the improvement of insulin
sensitivity in individuals with the metabolic syndrome: the GENOBIN study.
Diabetologia 51: 2060–2067.
19. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the
NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.
20. (2003) The International HapMap Project. Nature 426: 789–796.
21. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M,
et al. (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure
during migration of modern humans. Proc Natl Acad Sci U S A 104:
16645–16650.
22. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, et al.
(2008) Functional consequences of toll-like receptor 4 polymorphisms. Mol Med
14: 346–352.
23. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, et al. (2007)
Association of TLR4 polymorphisms with symptomatic respiratory syncytial
virus infection in high-risk infants and young children. J Immunol 179:
3171–3177.
24. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, et al. (2008) Toll-
like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.
N Engl J Med 359: 1766–1777.
25. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, et al. (2000) TLR4
mutations are associated with endotoxin hyporesponsiveness in humans. Nat
Genet 25: 187–191.
26. Smirnova I, Mann N, Dols A, Derkx HH, Hibberd ML, et al. (2003) Assay of
locus-specific genetic load implicates rare Toll-like receptor 4 mutations in
meningococcal susceptibility. Proc Natl Acad Sci U S A 100: 6075–6080.
27. van der Graaf C, Kullberg BJ, Joosten L, Verver-Jansen T, Jacobs L, et al.
(2005) Functional consequences of the Asp299Gly Toll-like receptor-4
polymorphism. Cytokine 30: 264–268.
28. Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, et al. (2003)
Effects of functional Toll-like receptor-4 mutations on the immune response to
human and experimental sepsis. Immunology 109: 426–431.
29. Illig T, Bongardt F, Schopfer A, Holle R, Muller S, et al. (2003) The endotoxin
receptor TLR4 polymorphism is not associated with diabetes or components of
the metabolic syndrome. Diabetes 52: 2861–2864.
30. Kolz M, Baumert J, Muller M, Khuseyinova N, Klopp N, et al. (2008)
Association between variations in the TLR4 gene and incident type 2 diabetes is
modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet
9: 9.
31. Buraczynska M, Baranowicz-Gaszczyk I, Tarach J, Ksiazek A (2009) Toll-like
receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients
with type 2 diabetes. Hum Immunol 70: 121–124.
32. Rudofsky G, Jr., Reismann P, Witte S, Humpert PM, Isermann B, et al. (2004)
Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a
reduced prevalence of diabetic neuropathy in patients with type 2 diabetes.
Diabetes Care 27: 179–183.
33. Bagarolli RA, Saad MJ, Saad ST (2009) Toll-like receptor 4 and inducible nitric
oxide synthase gene polymorphisms are associated with Type 2 diabetes.
J Diabetes Complications.
34. Steinhardt AP, Aranguren F, Tellechea ML, Gomez Rosso LA, Brites FD, et al.
(2010) A functional nonsynonymous toll-like receptor 4 gene polymorphism is
associated with metabolic syndrome, surrogates of insulin resistance, and
syndromes of lipid accumulation. Metabolism 59: 711–717.
35. Schafer S, Kantartzis K, Machann J, Venter C, Niess A, et al. (2007) Lifestyle
intervention in individuals with normal versus impaired glucose tolerance.
European Journal of Clinical Investigation 37: 535–543.
36. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:
539–553.
37. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome–a new
worldwide definition. Lancet 366: 1059–1062.
38. Machann J, Thamer C, Schnoedt B, Haap M, Haring HU, et al. (2005)
Standardized assessment of whole body adipose tissue topography by MRI.
J Magn Reson Imaging 21: 455–462.
39. Stefan N, Machicao F, Staiger H, Machann J, Schick F, et al. (2005)
Polymorphisms in the gene encoding adiponectin receptor 1 are associated with
insulin resistance and high liver fat. Diabetologia 48: 2282–2291.
40. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care 22: 1462–1470.
41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
42. Weyrich P, Machicao F, Staiger H, Simon P, Thamer C, et al. (2007) Role of
AMP-activated protein kinase gamma 3 genetic variability in glucose and lipid
metabolism in non-diabetic whites. Diabetologia 50: 2097–2106.
43. Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences
of Fatty liver. Endocr Rev 29: 939–960.
44. MacLaren R, Cui W, Cianflone K (2008) Adipokines and the immune system:
an adipocentric view. Adv Exp Med Biol 632: 1–21.
45. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue
tumor necrosis factor and interleukin-6 expression in human obesity and insulin
resistance. Am J Physiol Endocrinol Metab 280: E745–751.
46. Zha JM, Di WJ, Zhu T, Xie Y, Yu J, et al. (2009) Comparison of Gene
Transcription between Subcutaneous and Visceral Adipose Tissue in Chinese
Adults. Endocr J.
47. Zhang HM, Chen LL, Wang L, Xu S, Wang X, et al. (2009) Macrophage
infiltrates with high levels of Toll-like receptor 4 expression in white adipose
tissues of male Chinese. Nutr Metab Cardiovasc Dis.
48. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J,
et al. (2002) Fat accumulation in the liver is associated with defects in insulin
suppression of glucose production and serum free fatty acids independent of
obesity in normal men. J Clin Endocrinol Metab 87: 3023–3028.
49. Thamer C, Machann J, Stefan N, Haap M, Schafer S, et al. (2007) High visceral
fat mass and high liver fat are associated with resistance to lifestyle intervention.
Obesity (Silver Spring) 15: 531–538.
TLR4 and Body Fat Composition
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13980